Rxo (RXO) Capital Expenditures (2021 - 2026)

Rxo (RXO) has 6 years of Capital Expenditures data on file, last reported at $17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 13.33% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2026 stood at $61.0 million (up 24.49% YoY), and the FY2025 full-year result was $59.0 million, up 31.11% from the prior year.
• Capital Expenditures for Q1 2026 stood at $17.0 million, up from $16.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $18.0 million in Q4 2022 and bottomed at $11.0 million in Q1 2024.
• The 5-year median for Capital Expenditures is $14.0 million (2025), against an average of $14.2 million.
• The widest annual swing landed in 2022, when Capital Expenditures surged 100.0%; it then sank 38.89% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $18.0 million in 2022, then changed by 0.0% to $18.0 million in 2023, then tumbled by 33.33% to $12.0 million in 2024, then surged by 33.33% to $16.0 million in 2025, then climbed by 6.25% to $17.0 million in 2026.
• The last three Capital Expenditures figures came in at $17.0 million (Q1 2026), $16.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.

Peer Comparison